<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ict.sagepub.com">
<title>Integrative Cancer Therapies RSS feed -- OnlineFirst Articles</title>
<link>http://ict.sagepub.com</link>
<description>Integrative Cancer Therapies RSS feed -- OnlineFirst Articles</description>
<prism:publicationName>Integrative Cancer Therapies</prism:publicationName>
<prism:issn>1534-7354</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/1534735409352029v1?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/1534735409352084v1?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/1534735409352086v1?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/1534735409352083v1?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/1534735409352027v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ict.sagepub.com:80/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ict.sagepub.com:80/icons/banner/title.gif">
<title>Integrative Cancer Therapies</title>
<url>http://ict.sagepub.com:80/icons/banner/title.gif</url>
<link>http://ict.sagepub.com</link>
</image>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/1534735409352029v1?rss=1">
<title><![CDATA[Circadian Disruption, Per3, and Human Cytokine Secretion]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/1534735409352029v1?rss=1</link>
<description><![CDATA[
<p>Circadian disruption has been linked with inflammation, an established cancer risk factor. Per3 clock gene polymorphisms have also been associated with circadian disruption and with increased cancer risk. Patients completed a questionnaire and provided a blood sample prior to undergoing a colonoscopy (n = 70).Adjusted mean serum cytokine concentrations (IL-6, TNF-alpha, gamma-INF, IL-1ra, IL-1-beta, VEGF) were compared among patients with high and low scores for fatigue (Multidimensional Fatigue Inventory), depressive symptoms (Beck Depression Inventory II), or sleep disruption (Pittsburg Sleep Quality Index), or among patients with different Per3 clock gene variants. Poor sleep was associated with elevated VEGF, and fatigue-related reduced activity was associated with elevated TNF-alpha concentrations. Participants with the 4/5 or 5/5 Per3 variable tandem repeat sequence had elevated IL-6 concentrations compared to those with the 4/4 genotype. Biological processes linking circadian disruption with cancer remain to be elucidated. Increased inflammatory cytokine secretion may play a role.
]]></description>
<dc:creator><![CDATA[Guess, J., Burch, J. B., Ogoussan, K., Armstead, C. A., Zhang, H., Wagner, S., Hebert, J. R., Wood, P., Youngstedt, S. D., Hofseth, L. J., Singh, U., Xie, D., Hrushesky, W. J. M.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 21:33:18 PST</dc:date>
<dc:identifier>info:doi/10.1177/1534735409352029</dc:identifier>
<dc:title><![CDATA[Circadian Disruption, Per3, and Human Cytokine Secretion]]></dc:title>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/1534735409352084v1?rss=1">
<title><![CDATA[Per2 Is a C/EBP Target Gene Implicated in Myeloid Leukemia]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/1534735409352084v1?rss=1</link>
<description><![CDATA[
<p>Circadian rhythms are endogenous biological clocks that govern fundamental physiological and behavioral functions. Consequently, perturbations of these rhythms have been associated with pathogenic conditions, such as depression, diabetes, and cancer. CCAAT/enhancer-binding proteins (C/EBPs) are a family of transcription factors that regulate cell growth and differentiation in various tissues and have also been implicated in many cancer types. Using expression profiling studies,we found that the levels of 2 core components of the circadian network, Per2 and Rev-Erb,are significantly altered by C/EBPs. Further studies showed that levels of Per2 were reduced in lymphoma and acute myeloid leukemia patient samples, as well as in lymphoma cell lines. Overexpression of Per2 in hematopoietic cancer cell lines resulted in growth inhibition, cell cycle arrest, apoptosis and loss of clonogenic ability. These results support the emerging role of circadian genes in tumor suppression.
]]></description>
<dc:creator><![CDATA[Gery, S., Koeffler, H. P.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 21:33:17 PST</dc:date>
<dc:identifier>info:doi/10.1177/1534735409352084</dc:identifier>
<dc:title><![CDATA[Per2 Is a C/EBP Target Gene Implicated in Myeloid Leukemia]]></dc:title>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/1534735409352086v1?rss=1">
<title><![CDATA[Circadian Clock Manipulation for Cancer Prevention and Control and the Relief of Cancer Symptoms]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/1534735409352086v1?rss=1</link>
<description><![CDATA[
<p>Life has evolved on this planet with regular daily spans of direct solar energy availability alternating with nocturnal spans of dark. Virtually every earth-borne life form has factored this circadian pattern into its biology to ensure the temporal coordination with its resonating environment, a task essential for its individual survival and that of its species. The first whole genome inspections of mutations in human colon and breast cancer have observed specific retained clock gene mutations. Single nucleotide polymorphisms within the genes of clock, clock-controlled, and melatonin pathways have been found to confer excess cancer risk or protection from cancer. Experimental studies have shown that specific core clock genes (<I>Per2</I> and <I>Per1</I>) are tumor suppressors because their genetic absence doubles tumor numbers, and decreasing their expression in cancer cells doubles cancer growth rate, whereas their overexpression decreases cancer growth rate and diminishes tumor numbers. Experimental interference with circadian clock function increases cancer growth rate, and clinical circadian disruption is associated with higher cancer incidence, faster cancer progression, and shorter cancer patient survival. Patients with advanced lung cancer suffering greater circadian activity/sleep cycle disruption suffer greater interference with function, greater anxiety and depression, poorer nighttime sleep, greater daytime fatigue, and poorer quality of life than comparable patients who maintain good circadian integration. We must now determine whether strategies known to help synchronize the circadian clocks of normal individuals can do so in advanced cancer patients and whether doing so allows cancer patients to feel better and/or live longer. Several academic laboratories and at least 2 large pharmaceutical firms are screening for small molecules targeting the circadian clock to stabilize its phase and enhance its amplitude and thereby consolidate and coordinate circadian organization, which in turn is likely to help prevent and control human cancer. These drugs and strategies can, in turn, be used to make cancer patients with advanced disease feel and function more normally.
]]></description>
<dc:creator><![CDATA[Hrushesky, W. J., Grutsch, J. F., Wood, P., Yang, X., Oh, E.-Y., Ansell, C., Kidder, S., Ferrans, C., Quiton, D. F., Reynolds, J., Du-Quiton, J., Levin, R., Lis, C., Braun, D.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 21:33:17 PST</dc:date>
<dc:identifier>info:doi/10.1177/1534735409352086</dc:identifier>
<dc:title><![CDATA[Circadian Clock Manipulation for Cancer Prevention and Control and the Relief of Cancer Symptoms]]></dc:title>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/1534735409352083v1?rss=1">
<title><![CDATA[Circadian Time-Dependent Tumor Suppressor Function of Period Genes]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/1534735409352083v1?rss=1</link>
<description><![CDATA[
<p>The mammalian core clock genes, <I>Periods</I> (<I>Per1</I> and <I>Per2</I>), have tumor suppressor properties. Decreased expression of <I>Per1</I> and <I>Per2</I> has been reported in several types of human cancers. On the other hand, overexpression of <I>Per1</I> or <I>Per2</I> inhibits cancer cell growth in culture. The authors have shown that downregulation of <I>Per1</I> or <I>Per2</I> enhances cancer growth in vitro. These genes also regulate the amount of cell proliferation&ndash;related molecules, many of which are therapeutic targets. In animals, tumors grow with clear circadian organization, and <I>Per1</I> and <I>Per2</I> exert their tumor suppressor functions in a circadian time-dependent manner. Downregulation of <I>Per1</I> or <I>Per2</I> increases tumor growth only at certain specific times of the day. <I>Per1</I> and <I>Per2</I> differentially regulate tumor growth rhythm in vivo. These data suggest that the therapeutic efficacy of antiproliferation agents depends on the time of day of drug delivery. The optimal times of day may be shifted in tumors that have mutant <I>Period</I> genes.
]]></description>
<dc:creator><![CDATA[Yang, X., Wood, P., Ansell, C., Hrushesky, W. J.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 21:33:17 PST</dc:date>
<dc:identifier>info:doi/10.1177/1534735409352083</dc:identifier>
<dc:title><![CDATA[Circadian Time-Dependent Tumor Suppressor Function of Period Genes]]></dc:title>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/1534735409352027v1?rss=1">
<title><![CDATA[Nr1d1, an Important Circadian Pathway Regulatory Gene, Is Suppressed by Cigarette Smoke in Murine Lungs]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/1534735409352027v1?rss=1</link>
<description><![CDATA[
<p>Nuclear receptor subfamily 1,group D member 1 (<I>Nr1d1</I>),also known as <I>Rev-erb-</I>, belongs to the family of "orphan receptors" and functions as a member of clock gene family. In addition to being an important member of clock circuitry, <I>Nr1d1</I>, also regulates cell proliferation, lipid metabolism, and inflammation and is also touted as a tumor suppressor. Our focus on <I>Nr1d1</I> was stimulated by data from a genome-wide search for mRNA correlates of cigarette smoke (CS) sensitive&mdash;whole smoke (WS) and filtered smoke (FS)&mdash;lung transcriptomes in tumor-resistant C57BL6 and tumor-susceptible AJ mice strains. Differential analysis of ~15 000 genes using Affymetrix 430A 2.0 high-density oligonucleotide arrays identified modulation of genes related to circadian pathways by CS in lungs of both mouse strains. <I>Nr1d1</I> expression was downregulated by both WS and FS irrespective of mouse strain as compared to respective air-breathing controls. WS was more effective than FS on decreasing <I>Nr1d1</I> expression. The present data suggest that transcriptional regulation of <I>Nr1d1</I> by CS may affect circadian rhythmicity and thus may play a complementary role in CS-induced lung respiratory tract pathobiology and/or lung tumorigenesis.
]]></description>
<dc:creator><![CDATA[Vasu, V. T., Cross, C. E., Gohil, K.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 21:33:16 PST</dc:date>
<dc:identifier>info:doi/10.1177/1534735409352027</dc:identifier>
<dc:title><![CDATA[Nr1d1, an Important Circadian Pathway Regulatory Gene, Is Suppressed by Cigarette Smoke in Murine Lungs]]></dc:title>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

</rdf:RDF>